StockData
Arcturus Therapeutics Holdings Inc. logo

Arcturus Therapeutics Holdings Inc. (ARCT) stock

ARCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3010% below fair value
$7.97−0.34 (-4.09%)

Close on Nov 17, 2026Market cap $226.53MP/E –Yield –

Arcturus Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Arcturus Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$72.73M. For fiscal 2025 it was -$74.27M. The highest annual figure on record is $31.99M in fiscal 2022.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$74.27M–
FY2024Dec 31, 2024-$59.75M–
FY2023Dec 31, 2023-$18.10M-156.6%
FY2022Dec 31, 2022$31.99M–
FY2021Dec 31, 2021-$135.04M–
FY2020Dec 31, 2020-$42.86M–
FY2019Dec 31, 2019-$6.45M–
FY2018Dec 31, 2018-$20.76M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$19.91M–
Q1 FY2026Mar 31, 2026-$19.44M–
Q4 FY2025Dec 31, 2025-$16.23M–
Q3 FY2025Sep 30, 2025-$17.15M–
Q2 FY2025Jun 30, 2025-$5.76M–
Q1 FY2025Mar 31, 2025-$35.14M–
Q4 FY2024Dec 31, 2024-$284.00K–
Q3 FY2024Sep 30, 2024-$23.76M–
Q2 FY2024Jun 30, 2024-$30.14M-159.3%
Q1 FY2024Mar 31, 2024-$5.56M–
Q4 FY2023Dec 31, 2023-$629.00K-100.4%
Q3 FY2023Sep 30, 2023-$32.41M–
Q2 FY2023Jun 30, 2023$50.81M–
Q1 FY2023Mar 31, 2023-$35.87M–
Q4 FY2022Dec 31, 2022$160.26M–
Q3 FY2022Sep 30, 2022-$42.41M–
Q2 FY2022Jun 30, 2022-$36.82M–
Q1 FY2022Mar 31, 2022-$49.04M–
Q4 FY2021Dec 31, 2021-$42.50M–
Q3 FY2021Sep 30, 2021-$16.65M–
Q2 FY2021Jun 30, 2021-$32.94M–
Q1 FY2021Mar 31, 2021-$42.95M–
Q4 FY2020Dec 31, 2020-$6.63M–
Q3 FY2020Sep 30, 2020-$15.88M–
Q2 FY2020Jun 30, 2020-$8.49M-190.9%
Q1 FY2020Mar 31, 2020-$11.86M–
Q4 FY2019Dec 31, 2019-$7.54M–
Q3 FY2019Sep 30, 2019-$2.84M–
Q2 FY2019Jun 30, 2019$9.34M–
Q1 FY2019Mar 31, 2019-$5.41M–
Q4 FY2018Dec 31, 2018-$5.76M–
Q3 FY2018Sep 30, 2018-$6.80M–

More Arcturus Therapeutics figures

See a number that looks wrong?